0000000000530567

AUTHOR

Ignacio Herrero

showing 3 related works from this author

Controlling Diabetes After Liver Transplantation: Room for Improvement.

2016

BACKGROUND Diabetes mellitus is a chronic illness with great impact on long-term outcome after liver transplantation (LT). Despite this, the current level of glycemic control and quality of screening strategies for diabetes-associated conditions that are being provided to liver transplant recipients with diabetes have not yet been assessed. METHODS We performed a cross-sectional, multicenter study that included 344 liver transplant recipients and examined the level of glycemic control and its associated factors, as well as the quality of screening strategies for diabetes-associated conditions. RESULTS Seventy-five patients (21.8%) suffered from diabetes before transplantation, and 82 (23.8%…

Transplantationmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentDisease030230 surgeryLiver transplantationmedicine.diseaseNephropathyTransplantation03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineMedicine030211 gastroenterology & hepatologybusinessDyslipidemiaRetinopathyGlycemicTransplantation
researchProduct

Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

2016

Appropriate post-transplant immunosuppressive regimens that avoid acute rejection, while reducing risk of viral reactivation, have been sought, but remain a chimera. Recent evidence suggesting potential regulatory and antiviral effects of mammalian target of rapamycin inhibitors (mTORi) is of great interest. Although the concept of an immunosuppressive drug with antiviral properties is not new, little effort has been made to put the evidence together to assess the management of immunosuppressive therapy in the presence of a viral infection. This review was developed to gather the evidence on antiviral activity of the mTORi against the viruses that most commonly reactivate in adult solid org…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentHepatitis C virus030230 surgerymedicine.disease_causeAntiviral AgentsOrgan transplantationVirus03 medical and health sciencesChimera (genetics)0302 clinical medicinemedicineHumansImmunosuppression TherapyTransplantationEverolimusbusiness.industryTOR Serine-Threonine Kinasesvirus diseasesImmunosuppressionOrgan TransplantationTransplant RecipientsInfectious DiseasesImmunosuppressive drugVirus DiseasesSirolimusImmunology030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct

Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

2016

Cytomegalovirus (CMV) infection remains a major complication of solid organ transplantation. Because of management of CMV is variable among transplant centers, in 2011 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, new publications have clarified or questioned the aspects covered in the previous document. For that reason, a panel of experts revised the evidence on CMV management, including immunological monitoring, diagnostics, prevention, vaccines, indirect effects, tre…

medicine.medical_specialtyCongenital cytomegalovirus infectionMEDLINEDrug resistance030230 surgeryAntiviral AgentsOrgan transplantation03 medical and health sciences0302 clinical medicineMonitoring ImmunologicMedicineHumansMajor complicationIntensive care medicineTransplantationbusiness.industryOrgan Transplantationmedicine.diseaseTransplant RecipientsCytomegalovirus infectionClinical microbiologyImmunologyCytomegalovirus InfectionsPractice Guidelines as Topic030211 gastroenterology & hepatologybusinessSolid organ transplantationTransplantation reviews (Orlando, Fla.)
researchProduct